title: Fabrication of electrospun zein nanofibers for the sustained delivery of siRNA.
abstract: In this study, zein nanofibers based siRNA delivery system has been attempted for the first time. Here, the amphiphilic property of zein and the size advantage of nanofibers have been brought together in developing an ideal delivery system for siRNA. The morphological analysis of the GAPDH-siRNA loaded zein nanofibers revealed the proper encapsulation of the siRNA in the polymeric matrix. The loading efficiency of this delivery system was found to be 58.57±2.4% (w/w). The agarose gel analysis revealed that the zein nanofibers preserved the integrity of siRNA for a longer period even at the room temperature. The in vitro release studies not only depicted the sustaining potential of the zein nanofibers but also ensured the release of sufficient quantity of siRNA required to induce the gene silencing effect. The amphiphilic property of zein supported the cell attachment and thereby facilitated the transfection of siRNA into the cells. qRT-PCR analysis confirmed the potential of the developed system in inducing the desired gene silencing effect. Thus, electrospun zein nanofibers have been successfully employed for the delivery of siRNA which has a great therapeutic potential.
authors: Biomaterials Department, CSIR-Central Leather Research Institute, Adyar, Chennai, 600020, India.
authors: K
authors: K
authors: Karthikeyan
authors: Venkat Raghavan
authors: VR
authors: Krishnaswamy
authors: Rachita
authors: R
authors: Lakra
authors: M S
authors: MS
authors: Kiran
authors: Purna Sai
authors: PS
authors: Korrapati
mesh_terms: D002478:Cells, Cultured; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry*; D004595:Electroplating / Q000379:methods; D005347:Fibroblasts / Q000166:cytology / Q000502:physiology; D020868:Gene Silencing; D006801:Humans; D008297:Male; D008422:Materials Testing; D053769:Nanocapsules / Q000737:chemistry / Q000648:ultrastructure; D057139:Nanofibers / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics*; D012399:Rotation; D014162:Transfection / Q000379:methods*; D016896:Treatment Outcome; D015028:Zein / Q000737:chemistry*
chemical_list: D003692:Delayed-Action Preparations; D053769:Nanocapsules; D034741:RNA, Small Interfering; D015028:Zein
references: Oncogene. 2003 Sep 4;22(38):5938-45
references: 12955072
references: J Control Release. 2010 Jun 1;144(2):203-12
references: 20138939
references: J Control Release. 2003 Oct 30;92 (3):227-31
references: 14568403
references: Nucleic Acids Res. 2006;34(22):6561-73
references: 17135188
references: Mol Ther. 2009 Jan;17(1):95-103
references: 18957965
references: J Control Release. 2012 Jul 10;161(1):38-49
references: 22564368
references: J Control Release. 2007 Oct 18;123(1):1-10
references: 17716771
references: Biochem Biophys Res Commun. 2003 Dec 26;312(4):1220-5
references: 14652004
references: J Neurosci. 2007 Dec 26;27(52):14494-501
references: 18160657
references: Langmuir. 2008 Feb 5;24(3):965-74
references: 18076196
references: Mol Pharm. 2009 Mar-Apr;6(2):641-7
references: 19718809
references: Cancer Res. 2005 Oct 1;65(19):8984-92
references: 16204072
references: In Vitro Cell Dev Biol Anim. 1995 Jun;31(6):447-55
references: 8589888
references: J Control Release. 2003 Apr 29;89(2):341-53
references: 12711456
references: Gene Ther. 2013 Apr;20(4):378-85
references: 22717742
references: FASEB J. 2007 Sep;21(11):2664-71
references: 17463227
references: Int J Pharm. 2008 Nov 19;364(1):108-18
references: 18775770
references: J Control Release. 2010 Jul 14;145(2):149-58
references: 20362021
references: Angew Chem Int Ed Engl. 2011 Jul 25;50(31):7027-31
references: 21698724
references: Biofabrication. 2012 Jun;4(2):025008
references: 22592161
references: Mol Ther. 2006 Oct;14 (4):476-84
references: 16829204
references: Science. 2003 Mar 28;299(5615):2039-45
references: 12663920
references: J Nanobiotechnology. 2012 Dec 02;10:44
references: 23199119
references: Nature. 2004 Mar 25;428(6981):431-7
references: 15042092
references: Biomaterials. 2011 Sep;32(25):5915-23
references: 21596430
references: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references: 6606682
references: J Neurosci. 2004 Nov 10;24(45):10040-6
references: 15537872
references: Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7195-200
references: 12782788
references: Acta Biomater. 2010 Oct;6(10):4042-51
references: 20438870
references: Placenta. 2009 Feb;30(2):124-9
references: 19012963
references: Biomacromolecules. 2005 Jul-Aug;6(4):2017-24
references: 16004440
references: Nat Neurosci. 2005 Oct;8(10):1343-9
references: 16136043
references: Int J Pharm. 2012 Nov 15;438(1-2):117-22
references: 22960320
references: Nat Biotechnol. 2001 Nov;19(11):1029-34
references: 11689847
references: Int J Pharm. 2007 Oct 1;343(1-2):255-61
references: 17624698
references: Int J Mol Sci. 2013 Jan 14;14(1):1629-54
references: 23344060
references: Biomaterials. 2003 Nov;24(24):4353-64
references: 12922148
references: Nature. 2003 Jan 16;421(6920):231-7
references: 12529635